Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Watson-Actavis talks confirmed: merging geography and biosimilars

This article was originally published in Scrip

Executive Summary

It has been confirmed to Scrip by sources very close to the company that two of the world's leading generic medicines companies are negotiating a merger to create a company with generic drug sales approaching €6 billion. While the official line from both companies was no comment', various sources confirmed that a negotiation was taking place, that matters were close to being finalised, and that the expectation was that a deal would be concluded in the next few weeks.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts